40 results about "Pharmorubicin" patented technology

The invention discloses an antharcycline antitumor antibiotics loaded nano-micelle preparation, which comprises antharcycline antitumor antibiotics, A-B-C type triblock polymer and assisting agents, wherein the antharcycline antitumor antibiotics is one or more of adriamycin, daunorubicin, pharmorubicin, perarubicin or lacinomycin; and the A-B-C type triblock polymer is polyethylene glycol-polyethylene glycol containing carboxyl on side chain-polyester. According to the preparation, drugs are coated in the nano-micelle by virtue of the coaction of self-assembly of segmented copolymer and electrostatic adsorption, the nano-micelle has uniform and stable grain diameter, the encapsulation efficiency reaches 99 percent, and the prepared nano-micelle preparation is of a spherical structure with grain diameter between 20 and 300nm; and the shell of the micelle is made from polyethylene glycol molecules, so that drugs are prevented from being contacted with enzyme and other protein molecules in blood or identified and swallowed by a reticuloendothelial system in the body, so that the circulating period of micelle in the body can be prolonged.

The invention provides a polymer with a high-efficient drug loading performance, and a preparation method and application thereof. The polymer adopts poly(ethylene glycol)-b-poly [(N-2-hydroxyethyl)-asparaginate] as a basis, and is obtained through modification of phenylboronic acid. The polymer is prepared from main materials: polyethylene glycol and polyamino acid with favorable biocompatibility; a phenylboronic acid group of a polyamino acid side chain and a drug containing an amino group can achieve high-efficient drug loading through coordination interaction, the polymer has an ultrahighdrug loading rate (larger than 50 percent) and approximate 100 percent of encapsulation efficiency on clinically common chemotherapy drugs such as adriamycin, pharmorubicin and irinotecan, and the release of drug loading micelles has responsiveness of hydrogen peroxide; freeze-dried powder of the drug loading micelles has favorable redissolvability in a water solution, and a formed particle is small in particle size and narrow in distribution; meanwhile, the polymer is simple to prepare and convenient to popularize, and has a great development prospect in a biomedical material field, especially a drug delivery field.

The invention discloses a tumor targeted lipidosome drug-delivering system, a preparation method and an application. The system comprises a CRNGRGPDC polypeptide modified invisible lipidosome and an antitumor drug, wherein the invisible lipidosome comprises a) hydrogenated soyabean lecithin, b) cholesterol, c) polyethylene glycol-distearoyl phosphatidylethanolamine and d) distearoyl phosphatidylethanolamine-polyethylene glycol-CRNGRGPDC; the mole ratio of the components are as follows: a:b=(5-1):(1-5), a:c=1000:(0.1-100) and a:d=1000:(0.1-100); adriamycin amycin or pharmorubicin is taken as the antitumor drug; the weight percentage of the invisible lipidosome in the system is 75%-98%; the balance is the antitumor drug. The CRNGRGPDC provided by the invention is a cyclic peptide, is taken as aglucon and has pathoklisis with tumor cells. The invention also discloses the preparation method for the polypeptide modified lipidosome containing CRNGRGPDC sequence. The prepared polypeptide modified lipidosome containing CRNGRGPDC sequence is used for intravenous injection and is targeted to the tumor under the tumor EPR effect and CRNGRGPDC mediation. The lipidosome drug-delivering system can be used for targeting and delivering the drugs for tumor diagnosis or treatment.

The invention provides a sonodynamic liposomal material, a preparation method and an application thereof in preparing pharmorubicin composite liposomal. The liposomal material comprises 10-40mg of lecithin, 10mg of cholesterol, 5mg of chlorin, 3-5mL of saline citrate buffer solution of which the pH is 4-5 and 0.1-1mL of surfactant. The sonodynamic liposomal material mainly relates to the composite liposomal of pharmorubicin and sonochemical agent chlorin. The preparation method comprises the following steps of: combining the pharmorubicin and the chlorin into the lecithin with a film dispersion method-pH gradient method to form the composite liposomal; and better targeting the pharmorubicin composite liposomal into a tumor tissue to dually kill a tumor cell. The sonodynamic liposomal material is used for treating various tumors and has a good development prospect.

The invention discloses a method for treating bladder cancer through promoting pharmorubicin by a bacillus calmette guerin vaccine (BCG), and specifically relates to the field of combined treatment ofthe bladder cancer in clinical medicine. The method comprises a method for researching synergism of the BCG to the pharmorubicin in a cellular level and a method for synergism of the in-vivo BCG to the pharmorubicin. According to the invention, through using the method for researching the synergism of the BCG to the pharmorubicin in the cellular level and the method for the synergism of the in-vivo BCG to the pharmorubicin, a combined medication scheme is provided to improve treatment efficiency and reduce toxic and side effects during drug perfusion. The method disclosed by the invention isnot high in prefused drug concentration, but long in intra-bladder retention time, thereby being better in the anti-tumor effect without generating an adverse reaction.

The invention discloses a tumor-targeted multi-purpose nanometer drug delivery system as well as a preparation method and applications of the tumor-targeted multi-purpose nanometer drug delivery system. The system comprises multi-purpose nanoparticles modified by tumor penetrating peptide RGERPPR and an anti-tumor medicine, wherein the multi-purpose nanoparticles adopt the T1-T2 dual-mode magnetic resonance contrast agent; the anti-tumor medicine is adriamycin or pharmorubicin; and the weight of the anti-tumor medicine accounts for 10-35 % in the system. The drug delivery system has the following features: the grain diameter is 60-200 nm, and the particles are spherical; the T1 contrast agent Gd-DTPA and the T2 contrast agent Fe3O4 are simultaneously utilized, and the highly accurate diagnosis information is provided; the water solubility and biocompatibility of the medicine are improved, and the curative effects and bioavailability of the medicine are improved; the drug delivery system can be used for intravenous injection, and targets to the tumor tissue by utilizing the RGERPPR mediation effect and the tumor EPR effect, and the system has the obvious inhibiting effect for the growth of the brain glioma tumor; and the drug delivery system can be used for realizing the tumor diagnosis and treatment integration.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The disclosure relates to a method for culturing a chordoma organoid. The method comprises the steps: mixing chordoma tissue cells with a first culture medium and matrix glue, so as to obtain a firstpremix, wherein the first culture medium contains epirubicin, and the epirubicin has a concentration of 15mg/L to 25mg/L by taking the first culture medium as a reference; culturing the first premix for 3 to 7 days, so as to obtain a first culture; acquiring a liquid part from the first culture, and separating cell precipitate from the liquid part, wherein the cell precipitate contains chordoma cells; mixing the cell precipitate with a second culture medium and matrix glue, so as to obtain a second premix, wherein the second culture medium contains the epirubicin, and the epirubicin has a concentration of 5mg/L to 10mg/L by taking the second culture medium as a reference; and subjecting the second premix to culture amplification, thereby obtaining the chordoma organoid.

A nimustine slow release injection for treating solid cancer comprises slow release finding and nimustine, or the combination of nimustine and relative booster (pidorubicin, osaliplatinum, adriablastina, amethopterin or the like). The viscidity of slow-release injection is 10-650cp (20-30Deg. C). The anti-cancer effective component can be made into slow release plant agent. The slow release finding substantially comprises macromolecule polymer with biological soluble degradable and absorb property, which can slow release the anti-cancer effective component to cancer part in the degradation process, significantly reduce general reaction and hold effective drug density on cancer. The anti-cancer compound can be arranged part of cancer to reduce the general toxicity reaction, selectively improve the drug density locally, and strengthen the effect of non-surgery treatments as chemotherapy, and radiation therapy or the like. The solid cancer comprises glioma, lung carcinoma, intestinal cancer, breast cancer or the like.

The invention belongs to the technical field of medicines, and relates to a preparation method of epidoxorubicin lipidosome and application of the epidoxorubicin lipidosome in resisting tumors. The epidoxorubicin lipidosome is prepared from epidoxorubicin, at least one phospholipid, as well as at least one surfactant, cryoprotectant or cholesterol. Pharmacodynamic tests prove that the epidoxorubicin lipidosome has a remarkable anti-tumor effect, and can be used for treating diseases including but not limited to liver cancer, lung cancer and gastric cancer.

The invention provides applications of anthracene ring type compounds in preparation of medicines treating AIDS, especially applications of anthracene ring type compounds which are daunorubicin, doxorubicin, pharmorubicin, idarubicin and valrubicin in preparation of medicines treating AIDS. A human T lymphocyte line C8166 and an HIV-1 experimental strain that is HIV-1NL4-3 are selected to perform in-vitro cytotoxicity and anti-HIV activity experiments on the anthracene ring type compounds, wherein the cytotoxicity is detected by using an MTT colorimetric method, and the anti-HIV activity is detected by a symplasm inhibiting test method and an HIV-1p24 antigen quantification method. Through using different dosages of anthracene ring type medicines, results show that the anthracene ring type compounds have obvious anti-HIV effects so that the compounds can be applied for preparing medicines treating AIDS.

The invention provides a recombinant replication-defective adenovirus for expressing an hTERT (human telomerase reverse transcriptase) gene. A target gene hTERT is obtained by virtue of enzyme digestion from a plasmid pIRES2-EGFP(enhanced green fluorescent protein)-hTERT, the target gene hTERT is inserted to downstream of a cytomegalovirus promoter in a pSG218 shuttle vector to obtain a recombinant shuttle vector with the hTERT gene; and the recombinant shuttle vector and a virus framework vector pPE3-F11B are co-transferred to a human embryo kidney 293 cell to obtain replication-defective adenovirus with hTERT. The recombinant adenovirus infects a human multiple myeloma cell, so that the cell excessively expresses the hTERT gene, and therefore, drug resistance of the cell on pharmorubicin is strengthened. The recombinant replication-defective adenovirus disclosed by the invention is mainly used for establishing a multiple myeloma cell strain model for excessively expressing hTERT gene, and further researching a mechanism that the hTERT gene participates in drug resistance of the multiple myeloma cell based on the model.

The invention relates to an epirubicin (EPI) derivative with anticancer activity, in particular to a compound shown as a formula (I) and salts or solvates thereof, a preparation method of the compound shown as the formula (I) and application of the compound serving as medicinal active ingredients. The epirubicin derivative provided by the invention has the equivalent activity and even higher than that of the epirubicin in a cellular level. The formula (I) is shown in the description.

The invention provides an enhancer of a chemotherapeutic drug based on 1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-ectoine-2-ketone, and aims to enhance a chemotherapeutic effect of an anti-tumor drug. Under the same anti-tumor action, the use amount of the anti-tumor drug is effectively reduced, or under the same using dosage, the toxic and side effects of pharmorubicin are effectively reduced; furthermore, the pharmorubicin enhancer based on1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-ectoine-2-ketone can selectively enhance the killing effect of pharmorubicin on tumor cells, and reduce the side effect on normal cells.